Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum
<b>Background and Clinical Significance:</b> The mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a rare genetic alteration occurring in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the approved treatment for first-line therapy i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2571-841X/8/2/96 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849425639445102592 |
|---|---|
| author | Jacquelyn Shugarts Aida Amado Taylor Praska Monica Camou Jiaxin Niu |
| author_facet | Jacquelyn Shugarts Aida Amado Taylor Praska Monica Camou Jiaxin Niu |
| author_sort | Jacquelyn Shugarts |
| collection | DOAJ |
| description | <b>Background and Clinical Significance:</b> The mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a rare genetic alteration occurring in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the approved treatment for first-line therapy in a metastatic setting. However, the unusual presentation of gastrointestinal metastasis and leptomeningeal carcinomatosis (LMD) poses significant treatment challenges. <b>Case Presentation</b>: Here we report a case of a 72-year-old male with metastatic METex14-positive NSCLC, presenting with brain and duodenal metastases. <b>Conclusions</b>: The patient responded exceptionally well to first-line chemoimmunotherapy, achieving clinically complete remission for 2 years. He subsequently developed cerebellar metastasis and leptomeningeal disease (LMD) but demonstrated a remarkable response to tepotinib and continued to enjoy radiographic complete remission over 2.5 years at the time of this report. |
| format | Article |
| id | doaj-art-df7e4b7e3dfa440588fac72c3f304209 |
| institution | Kabale University |
| issn | 2571-841X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Reports |
| spelling | doaj-art-df7e4b7e3dfa440588fac72c3f3042092025-08-20T03:29:43ZengMDPI AGReports2571-841X2025-06-01829610.3390/reports8020096Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving DuodenumJacquelyn Shugarts0Aida Amado1Taylor Praska2Monica Camou3Jiaxin Niu4Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USADepartment of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USADepartment of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USADepartment of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USADepartment of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA<b>Background and Clinical Significance:</b> The mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a rare genetic alteration occurring in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the approved treatment for first-line therapy in a metastatic setting. However, the unusual presentation of gastrointestinal metastasis and leptomeningeal carcinomatosis (LMD) poses significant treatment challenges. <b>Case Presentation</b>: Here we report a case of a 72-year-old male with metastatic METex14-positive NSCLC, presenting with brain and duodenal metastases. <b>Conclusions</b>: The patient responded exceptionally well to first-line chemoimmunotherapy, achieving clinically complete remission for 2 years. He subsequently developed cerebellar metastasis and leptomeningeal disease (LMD) but demonstrated a remarkable response to tepotinib and continued to enjoy radiographic complete remission over 2.5 years at the time of this report.https://www.mdpi.com/2571-841X/8/2/96METex14 subtypeleptomeningealduodenal metastases |
| spellingShingle | Jacquelyn Shugarts Aida Amado Taylor Praska Monica Camou Jiaxin Niu Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum Reports METex14 subtype leptomeningeal duodenal metastases |
| title | Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum |
| title_full | Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum |
| title_fullStr | Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum |
| title_full_unstemmed | Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum |
| title_short | Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum |
| title_sort | treatment of leptomeningeal disease with tepotinib in a patient with lung adenocarcinoma harboring met exon 14 skipping mutation presenting with extensive metastasis involving duodenum |
| topic | METex14 subtype leptomeningeal duodenal metastases |
| url | https://www.mdpi.com/2571-841X/8/2/96 |
| work_keys_str_mv | AT jacquelynshugarts treatmentofleptomeningealdiseasewithtepotinibinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationpresentingwithextensivemetastasisinvolvingduodenum AT aidaamado treatmentofleptomeningealdiseasewithtepotinibinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationpresentingwithextensivemetastasisinvolvingduodenum AT taylorpraska treatmentofleptomeningealdiseasewithtepotinibinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationpresentingwithextensivemetastasisinvolvingduodenum AT monicacamou treatmentofleptomeningealdiseasewithtepotinibinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationpresentingwithextensivemetastasisinvolvingduodenum AT jiaxinniu treatmentofleptomeningealdiseasewithtepotinibinapatientwithlungadenocarcinomaharboringmetexon14skippingmutationpresentingwithextensivemetastasisinvolvingduodenum |